Here, we present new evidence that tumor-selective T-cell activation by TTS produces broad antitumor immune memory responses as monotherapy and in combination with PD-1/PD-L1 treatment that lead to the eradication of tumors, with a long-lasting antitumor response, in mice. The gene discussed is PDCD1; the disease is neoplasm.